ArticlePloS one2025
Immune subtyping of lymph node metastasis-negative colorectal cancer reveals biomarkers for prognosis and immunotherapy response.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymph node metastasis (LNM) is a key prognostic factor in colorectal cancer (CRC), and early lymph node status assessment is crucial for prognosis and immunotherapy decisions. However, the immune characteristics of LNM-negative CRC remain poorly understood.
methodsUsing machine learning algorithms, we identified and analyzed two immune subtypes (C1 and C2) in 244 LNM-negative CRC samples, with validation in 458 additional samples, and evaluated their immune characteristics and functional pathways.
resultsSubtype C1 exhibited high immune scores and responsiveness to immune checkpoint blockade, while subtype C2 showed a favorable prognosis and increased immune cell infiltration, indicating it represents an earlier CRC stage. Experimental validation revealed that PPFIA4 knockdown in C1 significantly suppressed CRC cell proliferation and migration.
conclusionsThese findings provide insights into personalized immunotherapy strategies for early-stage CRC patients and have potential clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.